The U.S. Department of Defense has introduced comprehensive guidelines for a new obligatory screening policy for testosterone deficiency among active-duty and reserve personnel aged 30 and above. This initiative follows a previous announcement made by U.S. Secretary of Defense Pete Hegseth in July.
The new guidelines, effective immediately, outline standardized screening and treatment protocols for both male and female service members. The Pentagon asserts that this initiative aims to enhance military readiness by identifying and addressing hormonal and energy-related issues.
Secretary Hegseth, a proponent of testosterone usage, disclosed the mandatory screening requirement last month, sparking discussions among experts regarding the scientific rationale behind the policy. The U.S. Food and Drug Administration is scheduled to convene a panel of experts in mid-September to discuss the medical application of testosterone.
As per the guidelines, males aged 30 and over will undergo compulsory testosterone blood tests, while younger males will be tested upon request or if warning signs are observed by healthcare providers. For females, routine testosterone blood tests are not mandated; however, screening for fatigue and menstrual irregularities associated with hormonal imbalances, low-energy availability, and relative energy deficiency in sport is recommended.
The guidance also provides directives on the appropriate use of off-label testosterone in women, particularly for postmenopausal individuals experiencing significantly reduced sexual desire. Some medical professionals have expressed concerns that widespread testosterone testing may result in unnecessary or potentially harmful treatments, citing a lack of evidence supporting the notion that universal screening for low testosterone levels would enhance U.S. military combat readiness.
